Navigation Links
ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Date:10/21/2008

- Multi-Center Study in Skin Graft Donor Site Patients -

ADDISON, Texas, Oct. 21 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced that it has commenced a clinical study to evaluate patients with graft donor sites treated with Altrazeal(TM) Silver compared with a market leading silver containing carboxymethylcellulose dressing. The study will be conducted at four clinical sites with 40 evaluable patients being enrolled. The first study site has been initiated and the Company plans to initiate additional sites within the next 30-days.

Each patient will have two skin graft donor sites, with Altrazeal(TM) Silver being applied to one site and the competitive dressing being applied to the other site. The primary study objective is to evaluate wound healing. Secondary study objectives include evaluating the incidence of wound infection, number of dressing changes, patient pain and provider and patient satisfaction.

This study is designed to support the marketing of Altrazeal(TM) Silver and provide the necessary clinical data to apply for a CE mark which will enable Altrazeal(TM) Silver to be marketed in Europe and Canada.

Commenting on the clinical study, Renaat Van Den Hooff, Executive Vice President of Operations stated, "Silver containing dressings are used extensively in the skin graft donor site indication to protect against infection. Preliminary data that has been generated in skin graft donor sites with Altrazeal(TM) is very positive, indicating that both patient comfort and pain are improved with Altrazeal(TM). With the use of silver containing dressings increasing in both chronic wounds and burns, this product line extension is an important component of our wound care franchise."

Silver has broad-spectrum antimicrobial properties which is ideal for use in preventing and treating infected wounds and wounds at risk of infection. Reducing bacteria burden in the wounds has been shown to improve healing. In preclinical studies, using a porcine wound healing model, Altrazeal(TM) silver showed superior healing rates compared to competitive silver dressings.

The company strategy is to develop a range of Altrazeal(TM) products incorporating active compounds for the treatment of the various phases of wound healing, infection, inflammation, debridement, maturation and closure. Altrazeal(TM) Silver will be the first product to demonstrate execution of this strategy (by implementing this strategy we believe that we will be delivering the products necessary to significantly improve wound healing).

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the response to the product from patients, the ability to use the product for chronic wounds, the product accelerates healing and decreases pain, decreases dressing changes and reduction in wound management nursing time. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company Media Contact:

Kerry P. Gray Stephen Zoegall, Ph.D.

President & CEO Berry & Co. Public Relations

Terry K. Wallberg (212) 253-8881

Vice President & CFO szoegall@berrypr.com

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
2. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
3. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
4. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
9. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
10. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
11. Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... JOLLA, Calif. , Feb. 23, 2017 ... company leading the discovery and development of innovative medicines ... and full year 2016 financial results on Thursday, March ... will host a conference call and webcast on March ... fourth quarter and full year 2016 financial results and ...
(Date:2/23/2017)... -- ... Research and Markets has announced the addition of the "Global Antifungal ... to their offering. The Global Antifungal Drugs Market is ... decade to reach approximately $12.8 billion by 2025. ... given segments on global as well as regional levels presented in the ...
(Date:2/23/2017)... Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company ... and market advanced products and therapies for the Wound ... sectors of healthcare, today announced its record results for ... 2016. Full Year 2016 Highlights are: ... full year 2015 revenue ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... ... host a diverse symposium on “Doping in Sport: How the Culture Might ... Richter & Hampton LLP. The symposium will be held at Pepperdine University in ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in clinical trials, today announced that Premier Research, a leading clinical development service ... Clinical trials are becoming increasingly complex, due in part to an array of ...
(Date:2/23/2017)... ... February 23, 2017 , ... The ... the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld to ... autism spectrum disorder (ASD) to see films in an environment that accommodates their ...
(Date:2/23/2017)... Los Angeles, CA (PRWEB) , ... February 23, 2017 , ... ... of her Smiling Patriot program today with a new Indiegogo campaign ... dental care to homeless veterans in the Los Angeles area, either as a participating ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... Thomas ... perseverance and disciplined exercise regime, the author was able to successfully recover. In “ ... all relevant information for various sources on the principals of massage, anatomy , ...
Breaking Medicine News(10 mins):